The Ministry of Health has announced the introduction of new drugs both in drug programmes and on the pharmacy list from January. The refund will cover further therapies for breast cancer patients. What is more, new reimbursed drugs will appear in the treatment of, among others, diabetes, depression, severe allergic asthma or hepatitis B.
New oncological therapies
The January reimbursement list provides for new therapeutic options for the treatment of important cancer diseases. For example, patients treated for breast cancer will gain new treatment options both in drug programmes and in pharmacy reimbursement. The reimbursement will include Kadycla (trastuzumab emtanisin) in the drug programme: “Treatment of breast cancer”. And for patients with breast cancer in the indication “Hormone dependent and HER2-negative breast cancer in the 1st throw of hormone therapy for advanced cancer (possible earlier use of complementary hormone therapy for early breast cancer) in cases other than the CTP” the list provides for the introduction of products containing anastrosol, letrozole and exemestane into the pharmacy reimbursement.
Gazyvaro (obinutuzumab) will be used in the first and subsequent lines of treatment in the programme “Treatment of malignant lymphoma patients (ICD – 10 C82, C83)”. It is worth noting that the price of this biological drug manufactured by Roche has been reduced by 25% in all reimbursement indications. Moreover, patients with acute myelogenous leukaemia will have extended indications of Vidaza (azacitidinum), so that a wider range of patients can be treated.
The Ministry of Health reports that a total of ten new active substances were introduced in 2019 as part of the reimbursement of oncological diseases. This means an increase of almost 20%.
New drugs: diabetes, depression, asthma, hepatitis B
Numerous changes will occur on the pharmacy list for the therapy of diabetes, as a result of which diabetics will receive new drugs, including Trulicity (dulaglutidum) and Ozempic (semaglutidum), used in patients with type 2 diabetes, prior to the inclusion of insulin, treated with at least two oral hypoglycemic drugs for at least 6 months. Another therapeutic option available from January will be Ryzodeg (insulinum degludecum + insulinum aspartum), according to data provided by the Ministry of Health.
In addition, new therapies to help treat depressive disorders will be available on the pharmacy list. Depratal (duloxetine) will be reimbursed in the indication “Treatment of major depressive disorders and Brintellix (vortioxetine) in the indication “Treatment of major depressive episodes in adults in whom no improvement has been achieved in the treatment of the current episode despite the use of a drug from the group of selective serotonin reuptake inhibitors or from the group of serotonin and noradrenaline reuptake inhibitors. The pharmacy list will also include Trevicta (paliperidone), a new form of drug with this active substance, with prolonged release, which will be available to patients for, among other things, the treatment of maintaining schizophrenia.
The therapy options for Xolair (omalizumab), which will be reimbursed to paediatric patients aged 6-11 years, have been extended under the drug program “Treatment of severe allergic IgE dependent and severe eosinophilic asthma”. It will also be available under the new drug programme “Treatment of chronic spontaneous urticaria”.
The reimbursement is also available in off-label indications for drugs containing the active substances entekavir and tenofovir as part of the new drug programme “Prevention of hepatitis B hepatitis B reactivation in post-transplant recipients or in recipients receiving treatment related to the risk of HBV reactivation”.